ICE Pharma Group

Pharmacy Market

Boston Scientific | December 02, 2020

Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections. "...

Business Insights

Innovent Biologics | September 02, 2021

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and GenFleet Therapeutics (Shanghai) Inc., a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, today jointly announced that they have entered into an exclusive license agreement for the development and commercialization of GenFleet&...

WRAL TechWire | February 11, 2020

Mycovia Pharmaceuticals, a developer of drugs in women’s health, has initiated “extension studies” as part of its ongoing Phase 3 global clinical trial of its lead drug candidate for treating recurrent yeast infections in women. The Durham-based firm is developing oteseconazole (VT-1161), an oral antifungal product candidate, for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwi...

Business Insights

Catalent, Inc. | August 10, 2022

Catalent, Inc. the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services a full-service specialty Contract Development and Manufacturing Organization with a facility in Greenville, North Carolina, for $475 million from Mayne Pharma Group Limited. Upon completion, the acquisition will stre...